$12.7M
$560K
3.0x
Subscribe Free
Read the full deal writeup
Sign up for a free Accredited account to read the editorial writeup, financials, and broker contact for this deal.
Get Free AccessFull Editorial Writeup
This pharmacy is fully staffed and easily operated by an absentee owner. Direct contracts with many pharma manufactures. Established Prior-Authorization P&P. Pharma voucher program contracts in place. Annual Sales $12,656,546.00 Gross Profit $1,239,635.60 EBITDA $559,528.00 Annual Rx Count 29081 Asking...
Why we like it
- Defensive healthcare demand with 29K annual prescriptions creating predictable recurring revenue base. Prescription volume provides steady cash generation that's largely recession-resistant, and the established patient base represents significant switching costs and local market entrenchment.
- Direct manufacturer contracts and established prior authorization processes indicate operational sophistication beyond typical small pharmacy. These relationships can drive better purchasing terms and streamline fulfillment, directly impacting gross margins in a thin-margin business.
- Pharma voucher program participation suggests revenue diversification beyond basic dispensing fees. These programs often carry higher margins and demonstrate the pharmacy's ability to navigate complex payer relationships, creating additional revenue streams from manufacturer partnerships.
- Absentee-ready operations with full staffing implies systems-dependent business rather than owner-dependent. This reduces integration risk and allows new owner to immediately focus on growth initiatives rather than operational stabilization, while existing staff provides continuity of patient relationships.
How to improve it
- Audit payer mix and negotiate higher reimbursement rates with top insurance plans within first 60 days. Most independent pharmacies accept whatever rates are offered, but active negotiation based on volume and service levels can improve margins by 1-2% with minimal effort.
- Implement clinical services like immunizations, blood pressure monitoring, and medication therapy management to capture additional revenue per patient visit. These services typically carry 60-80% margins and differentiate from chain competitors while increasing customer stickiness.
- Optimize inventory management through better forecasting and automated reordering systems to reduce carrying costs and improve cash conversion. Independent pharmacies often over-stock slow-movers, tying up significant working capital that could improve cash flow by 10-15%.
- Expand manufacturer voucher and patient assistance programs beyond current contracts to capture more high-value specialty prescriptions. These programs often provide guaranteed margins and can significantly boost per-prescription revenue for chronic condition medications.
- Develop compounding capabilities for dermatology, veterinary, or hormone replacement therapy to access higher-margin specialty markets. Compounding commands 3-5x typical dispensing margins and creates differentiation that's difficult for chains to replicate.
- Launch medication synchronization program to improve patient adherence and create predictable monthly revenue cycles. Sync programs typically increase prescription volume per patient by 15-20% while improving cash flow predictability.
- Negotiate group purchasing organization membership to improve wholesale drug costs and access to generic alternatives. GPO membership can reduce drug costs by 2-3%, directly flowing to bottom line in a thin-margin business.
- Implement delivery services and automated prescription packaging to capture market share from chain competitors and improve patient convenience. These services command premium pricing while increasing customer retention and prescription volume per patient.
Diligence notes
- Verify payer mix breakdown and reimbursement trends, particularly Medicare Part D and major commercial plans. Declining reimbursement rates are killing independent pharmacies, and this 9.8% gross margin suggests potential pressure that needs deeper investigation before assuming sustainability.
- Analyze prescription volume trends by therapeutic category and identify any concentration risk in specific drug classes or patient populations. Heavy dependence on particular medications facing generic competition or formulary changes could crater volumes without warning.
- Review controlled substance licensing, DEA compliance history, and any regulatory issues that could impact operations. Pharmacy licenses are complex to transfer and any compliance issues could delay closing or require expensive remediation post-acquisition.
- Examine lease terms, renewal options, and any restrictive covenants that might limit operational flexibility or create succession risk. Many pharmacy leases contain specific use clauses and personal guarantees that complicate ownership transitions and operational changes.